All In Biotech

Drug Trial Radar · NCT04676633

Safety, Tolerability, PK, Anti-Tumor Activity of STP705 in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy

Phase 1 Multicenter, Open-Label, Dose Escalation Study and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of STP705 Administered Intratumorally in Cholangiocarcinoma, Hepatocellular Carcinoma or Liver Metastases in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy

Last checked: Nov 19, 2026Latest source record: Mar 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

5

Actual

Start

Mar 1, 2021

Primary completion

Jan 13, 2023

Study completion Jan 13, 2023

Sponsor

Lead sponsor
SirnaomicsIndustry
Sponsor type
Industry
Collaborators
Translational Drug Development
First posted
Dec 21, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of STP705 administered intratumorally in cholangiocarcinoma, hepatocellular carcinoma or liver metastasis in subjects with advanced/metastatic or surgically unresectable solid tumors who are refractory to standard therapy. Goals: 1. To determine the MTD or RP2D of STP705 when administered intratumorally into cholangiocarcinoma, hepatocellular carcinoma, or liver metastasis. 2. To establish the dose of STP705 recommended for future phase 2 studies when administered intratumorally.

Conditions

  • Hepatocellular Carcinoma
  • Liver Metastases
  • Cholangiocarcinoma

Interventions

  • STP705Drug

    Investigational Product

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Tolerated Dose (MTD)Time frame: 28 day cycle
  2. Limited Dose Toxicity (LTD)Time frame: 28 day cycle

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Honor Health

    Scottsdale, Arizona

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California

  • Norton Cancer Institute

    Louisville, Kentucky

  • Atlantic Health System

    Morristown, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.